Accelevir develops translational biomarkers to enable data-driven decision-making from preclinical discovery through late-phase clinical studies.
- Molecular Biomarkers – Quantitative nucleic acid detection (dPCR, qPCR, NGS) for viral load, transgene persistence, and gene editing efficiency.
- Immune Biomarkers – Flow cytometry, ELISpot, ICS, and cytokine multiplexing for innate and adaptive immune profiling.
- Regulatory Alignment – Fit-for-purpose and fully validated assays that meet IND, BLA, and NDA submission standards.
- Cross-Platform Integration – Combining molecular and immune biomarker datasets to support mechanism-of-action and efficacy analysis.